Skedulo Raises $75M in Series C Surpassing 35 Million Appointments Scheduled

Skedulo, the leader in deskless productivity software, today announced the company raised $75M in its series C, led by SoftBank Vision Fund 2*, and celebrated the booking of 35M appointments through its platform. “This year proved the significant need for deskless scheduling and productivity technology worldwide, and we will leverage the latest funding to continue to push the limits of innovation.” Skedulo played a critical role in the fight against COVID-19, first assisting frontline workers with COVID-19 testing, having been selected by BioReference Laboratories, an OPKO Health company, to co-create a high capacity scheduling solution, and then with the vaccination rollout, partnering with governments globally like the country of New Zealand, the province of Ontario, and several U.S. states - including California, Maine, Maryland, North Carolina, Ohio and more. “We needed an efficient, agile and frictionless platform to optimize our patient-centric experience,” said Vinny Pacione, Vice President, Consumer Technology and Digital Solutions at BioReference Laboratories. Powered by AI and machine learning, Skedulo’s cloud-based software helps enterprises increase productivity by enabling them to intelligently manage and support deskless workforces,” said Priya Saiprasad, Partner at SoftBank Investment Advisers. Skedulo has enabled hundreds of organizations, including The American Red Cross, DHL, and Sunrun, to seamlessly schedule and service over 35 million appointments worldwide.